Spravato is the brand name for the FDA-approved intranasal esketamine treatment supplied by Janssen. It is exactly the same substance as all other esketamine discussed in this article. It ships as a nasal spray formulation to facilitate use by patients.
The FDA approved Spravato for two indications. An indication is a medical term for a disease state in which treatment would be appropriate.
The first indication is for adults with treatment-resistant depression. The second indication is for adults with major depressive disorder with suicidal thoughts or actions. To determine your eligibility, you will need to discuss your situation with a qualified mental health provider.
Janssen is a leading pharmaceutical company with a history of successful psychiatric medicines. FDA regulation of esketamine production at Janssen facilities ensures quality control and safety.
Janssen maintains the patent on esketamine treatment for this use. Therefore, it is the primary supplier of esketamine for treatment-resistant depression.
The Janssen website supplies all official documents and information regarding Spravato. This includes prescribing information, boxed warnings, and a medication guide. It is important to use this information as a reference when discussing Spravato with your provider.